Received Oct 23, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | 1 | — | — |
| MENB | MENINGOCOCCAL B (TRUMENBA) | PFIZER\WYETH | 1 | — | — |
Patient received 1 dose of Trumenba in October 2023. Patient received 1 dose of Bexsero in October 2025.; This non-serious case was reported by a physician via call center representative and described the occurrence of interchange of vaccine products in a patient who received Men B NVS (Bexsero) for prophylaxis. Co-suspect products included Meningococcal vaccine B rfHbpA/fHbpB (Trumenba) for prophylaxis. In OCT-2025, the patient received the 1st dose of Bexsero. In OCT-2023, the patient received the 1st dose of Trumenba. In OCT-2025, an unknown time after receiving Bexsero and an unknown time after receiving Trumenba, the patient experienced interchange of vaccine products (Verbatim: Patient received 1 dose of Trumenba in October 2023. Patient received 1 dose of Bexsero in October 2025.). The outcome of the interchange of vaccine products was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 06-OCT-2025 The patient received 1 dose of Trumenba and 1 dose of Bexsero. The reporter asked was a second dose of Bexsero required. The batch number was not provided upon follow up with the reporter.